Day: February 13, 2024

Mullen Automotive Inc. (NASDAQ: MULN), is updating its press release with certain corrections as described further below. There are no changes to the financial results for the three months ended Dec. 31, 2023. The prior press release as corrected is set forth in its entirety below. Company reports financial results and current business update Stockholders’ equity $271,814,097.00 as of December 31, 2023 BREA, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announces financial results for the three months ended Dec. 31, 2023, and a business update. Commenting on the results for the three months ended Dec. 31, 2023, and recent Company developments, CEO and chairman David Michery stated, “We are coming off our strongest quarter to...

TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) — Clairvest Group Inc. (TSX: CVG) today reported results for the fiscal 2024 third quarter and nine months ended December 31, 2023. (All figures are in Canadian dollars unless otherwise stated) HighlightsDecember 31, 2023 book value was $1,150.3 million or $78.38 per share compared with $1,181.0 million or $78.61 per share as at September 30, 2023 Net loss for the quarter ended December 31, 2023 was $5.0 million or $0.34 per share Net loss for the nine months ended December 31, 2023 was $29.5 million or $1.97 per share Clairvest repurchased for cancellation 340,100 shares from a passive shareholder for a total cost of $25.2 millionClairvest’s book value was $1,150.3 million or $78.38 per share as at December 31, 2023, compared with $1,181.0 million or $78.61 per share as at September...

FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development plans HALIFAX, Nova Scotia, Feb. 13, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023. All figures are stated in Canadian dollars unless otherwise stated. In recent months, we’ve achieved significant milestones by solidifying ATI-1701 government...

MONTREAL, Feb. 13, 2024 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or “the Corporation”) (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the three and six-month period ended December 31, 2023. All amounts in this press release are in Canadian dollars, unless otherwise stated. HIGHLIGHTSTotal revenues of $29,063,024 in Q2-2024 compared to $31,725,122 in Q2-2023, representing an 8% decrease due to a 6-week strike at one of our major customers; Gross margin on revenues from customers of 19.4% in Q2-2024 compared to 17.8% in Q2-2023 and of 19.5% for YTD 2024 compared to 14.9% for YTD 2023; Adjusted EBITDA* of $416,000 in Q2-2024 compared to $141,300 in Q2-2023 for the advanced materials, plastics and composite products; Adjusted EBITDA* of -$508,806 in Q2-2024 compared to...

VANCOUVER, British Columbia, Feb. 13, 2024 (GLOBE NEWSWIRE) — Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) reported a net loss of $14.3 million in the fourth quarter of 2023, as compared to a net loss of $17.4 million in the third quarter of 2023, and net loss of $21.4 million in the fourth quarter of 2022. Results in the fourth quarter of 2023 reflect lower realized pricing and shipment volumes on a stronger lumber sales mix, offset by lower stumpage rates as compared to the same period last year. Adjusted EBITDA was negative $1.2 million in the fourth quarter of 2023, as compared to negative $11.6 million in the third quarter of 2023, and negative $11.9 million in the fourth quarter of 2022. Operating loss prior to restructuring and other items was $14.4 million in the fourth quarter of 2023, as compared...

CARLSBAD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $3.1 million, or $0.52 per diluted share, on net sales of $25.2 million for the second quarter of fiscal year 2024 compared to net income of $1.8 million, or $0.31 per diluted share, in the second quarter of the prior fiscal year. Net sales during the three months ended December 31, 2023, decreased $17.1 million, or 40%, to $25.2 million as compared to $42.3 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales decreased 44% to $23.0 million. Private-label contract manufacturing sales decreased primarily due to reduced orders...

ARCHBOLD, Ohio, Feb. 13, 2024 (GLOBE NEWSWIRE) — Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) today reported financial results for the 2023 fourth quarter and twelve months ended December 31, 2023. 2023 Fourth Quarter Financial and Operating Highlights (on a year-over-year basis unless noted):83 consecutive quarters of profitability Net income was $5.5 million, or $0.41 per basic and diluted share Asset quality remains strong as nonperforming loans were 0.87% of total loans Net charge-offs to average loans were 0.03% Allowance for credit losses was 111.95% of nonperforming loans Tier 1 leverage ratio was 8.20% Opened first bank office in Michigan and new regional headquarters in Fort Wayne, Indiana Added Ian D. Boyce to the Board of Directors of both the Company and the Bank Realigned organizational structure to support...

HighlightsFourth quarter revenue of $2.6 billion; net income attributable to GXO of $73 million; adjusted EBITDA1 of $193 million; diluted EPS of $0.61 and adjusted diluted EPS1 of $0.70 Full year revenue of $9.8 billion; net income attributable to GXO of $229 million; adjusted EBITDA1 of $741 million; diluted EPS of $1.92 and adjusted diluted EPS1 of $2.59 Full year cash flows from operations of $558 million, equivalent to 244% of net income attributable to GXO, and free cash flow1 of $302 million, equivalent to 41% of adjusted EBITDA1 Announced 2024 guidance2:Organic revenue growth1 of 2%-5% Adjusted EBITDA1 of $760-$790 million Adjusted diluted earnings per share1 of $2.70-$2.90 Free cash flow conversion1 of 30%-40% of adjusted EBITDA1Business HighlightsSigned more than $1 billion annualized revenue in 2023; ~40% from outsourcing ~$600...